课题基金 / 基金详情

PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)

PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)
9-CIS 视黄酸 (ALRT 1057) 在 AIDS-KS (AMC PROT.002) 中的 II 期试验
批准号：
6118446
负责人：
STEVEN MILES
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118446
关键词：
AIDS therapy HIV infections Kaposi's sarcoma antineoplastics clinical research cytotoxicity dosage drug adverse effect drug screening /evaluation human immunodeficiency virus human subject human therapy evaluation neoplasm /cancer chemotherapy neoplastic growth opportunistic infections retinoate

项目摘要

项目成果

STEVEN MILES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Kaposi's sarcoma (KS) is a type of cancer that is related to the infection with the human immunodefiency virus (HIV). The only treatment that consistently causes the tumor to shrink in all patients is the use of cancer chemotherapy drugs and interferons.Recent laboratory studies suggest that a new vitamin A-lik chemical, 9-cis-RA(ALRT1057) can slow the growth of this type of cancer cells in the laboratory.This drug can significant side effects.This research study will give increasing doses of 9-cis-RA to determine the safety and toxic side effects
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)
DOSE ESCALATING STUDY OF CUTANEOUS AIDS RELATED KAPOSI'S SARCOMA
STEM CELL MOBILIZATION AND HARVESTING FROM THE PERIPHERAL BLOOD
PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS
海外基金